Courtney Calkins
Physician Assistant · Brighton, MINPI 1164977781
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 861 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 36 manufacturers reported payments, led by Johnson & Johnson at 27.9% of the total. Reporting peaked in 2023 at $4,327 and has fallen 87.6% since, to $535 in 2025. Among physician assistant clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 861 payments — averaging $16.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$4K
- Amgen$2K
- UCB, Inc.$2K
- AbbVie$1K
- Novartis$911
- AstraZeneca$633
- plus $3K from 30 others
What the payments were for
- Food & beverage$13,96897%
- Education$4343%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 335 | $4,022 |
| Amgen(2 entities) | 134 | $2,439 |
| UCB, Inc. | 67 | $1,769 |
| AbbVie | 95 | $1,436 |
| Novartis | 41 | $911 |
| AstraZeneca(2 entities) | 29 | $633 |
| Mallinckrodt Hospital Products Inc. | 24 | $504 |
| E.r. Squibb & Sons, L.L.C. | 28 | $396 |
| Lilly USA, LLC | 12 | $258 |
| ANI Pharmaceuticals, Inc. | 13 | $256 |
| Pfizer | 17 | $245 |
| Organon | 10 | $211 |
| Cvrx, Inc. | 2 | $196 |
| Boehringer Ingelheim | 8 | $179 |
| Janssen Scientific Affairs, LLC | 2 | $172 |
| Merck | 3 | $70 |
| Regeneron Healthcare Solutions, Inc. | 3 | $69 |
| Genentech USA, Inc. | 5 | $69 |
| GSK | 4 | $60 |
| Aurinia Pharma U.S., Inc. | 3 | $57 |
| Sandoz | 3 | $55 |
| Sobi, Inc | 3 | $47 |
| Sanofi | 2 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Radius Health, Inc. | 3 | $40 |
| Alvogen Inc | 2 | $34 |
| Bioventus LLC | 2 | $27 |
| Actelion Pharmaceuticals US, Inc. | 1 | $27 |
| United Therapeutics Corporation | 1 | $25 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Fidia Pharma USA Inc. | 1 | $16 |
| Mylan Institutional Inc. | 1 | $14 |
| Biocon Biologics Inc | 1 | $14 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $13 |
| Alnylam Pharmaceuticals Inc. | 1 | $13 |
| US Oncology Corporate, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Barostim Neo System$171
- SAPHNELO$118
- Tavneos$114
- Tremfya$100
How this compares
$14,402 in reported general payments places this provider in the 95th percentile of 5,453 physician assistant providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 27 | $187,099 |
| Humira(Cf) PenAdalimumab | 25 | $180,073 |
| Cosentyx Sensoready PenSecukinumab | 18 | $144,099 |
| OtezlaApremilast | 30 | $116,565 |
| Humira PenAdalimumab | 14 | $97,034 |
| Orencia ClickjectAbatacept | 12 | $73,579 |
| Teriparatide | 18 | $33,032 |
| Hydroxychloroquine Sulfate | 287 | $22,845 |
| MethotrexateMethotrexate Sodium | 204 | $7,897 |
| Mycophenolate Mofetil | 11 | $2,613 |
| Febuxostat | 15 | $2,324 |
| Leflunomide | 46 | $1,792 |
| Levothyroxine Sodium | 19 | $1,504 |
| Sulfasalazine | 34 | $1,437 |
| Sulfasalazine DrSulfasalazine | 21 | $1,319 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $2,439 | $116,56530 claims |
| Alvogen IncTeriparatide | $34 | $33,03218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,453 physician assistant providers in Michigan.
Other physician assistant in Brighton
- Sarang PatelRoyal Oak$660K
- Beth SweneyAda$617K
- Zainab JishiCanton$596K
- Taylor HennrickAdrian$430K
- Erin van DykeGrand Rapids$346K
- Ashley AldridgeAnn Arbor$298K
- Derek SusallaRochester Hills$242K
- Gabrielle DamoreRoyal Oak$200K
- Melissa MickelsonKalamazoo$168K
- Patrick CooneyNew Baltimore$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.